• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

前列腺癌分期预测模型的评估。

Evaluation of prediction models for the staging of prostate cancer.

机构信息

UCD School of Medicine and Medical Science, University College Dublin, Dublin, Ireland.

出版信息

BMC Med Inform Decis Mak. 2013 Nov 15;13:126. doi: 10.1186/1472-6947-13-126.

DOI:10.1186/1472-6947-13-126
PMID:24238348
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3834875/
Abstract

BACKGROUND

There are dilemmas associated with the diagnosis and prognosis of prostate cancer which has lead to over diagnosis and over treatment. Prediction tools have been developed to assist the treatment of the disease.

METHODS

A retrospective review was performed of the Irish Prostate Cancer Research Consortium database and 603 patients were used in the study. Statistical models based on routinely used clinical variables were built using logistic regression, random forests and k nearest neighbours to predict prostate cancer stage. The predictive ability of the models was examined using discrimination metrics, calibration curves and clinical relevance, explored using decision curve analysis. The N = 603 patients were then applied to the 2007 Partin table to compare the predictions from the current gold standard in staging prediction to the models developed in this study.

RESULTS

30% of the study cohort had non organ-confined disease. The model built using logistic regression illustrated the highest discrimination metrics (AUC = 0.622, Sens = 0.647, Spec = 0.601), best calibration and the most clinical relevance based on decision curve analysis. This model also achieved higher discrimination than the 2007 Partin table (ECE AUC = 0.572 & 0.509 for T1c and T2a respectively). However, even the best statistical model does not accurately predict prostate cancer stage.

CONCLUSIONS

This study has illustrated the inability of the current clinical variables and the 2007 Partin table to accurately predict prostate cancer stage. New biomarker features are urgently required to address the problem clinician's face in identifying the most appropriate treatment for their patients. This paper also demonstrated a concise methodological approach to evaluate novel features or prediction models.

摘要

背景

前列腺癌的诊断和预后存在诸多困境,导致过度诊断和过度治疗。预测工具的开发旨在协助治疗这种疾病。

方法

对爱尔兰前列腺癌研究联合会数据库进行回顾性研究,共纳入 603 例患者。采用逻辑回归、随机森林和 K 最近邻算法等统计模型,基于常用的临床变量构建预测模型,以预测前列腺癌分期。采用判别度量、校准曲线和临床相关性评估模型的预测能力,并通过决策曲线分析进行探索。将 603 例患者应用于 2007 年 Partin 表,比较当前分期预测的金标准与本研究中开发的模型的预测结果。

结果

研究队列中有 30%的患者存在非器官局限性疾病。采用逻辑回归构建的模型具有最高的判别度量(AUC=0.622,Sens=0.647,Spec=0.601)、最佳校准和基于决策曲线分析的最佳临床相关性。该模型在预测 T1c 和 T2a 期时,也比 2007 年 Partin 表具有更高的判别能力(ECE AUC 分别为 0.572 和 0.509)。然而,即使是最佳的统计模型也无法准确预测前列腺癌分期。

结论

本研究表明,当前的临床变量和 2007 年 Partin 表无法准确预测前列腺癌分期。迫切需要新的生物标志物特征来解决临床医生在为患者确定最合适的治疗方案时面临的问题。本文还展示了一种简洁的方法学方法,用于评估新的特征或预测模型。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8f1/3834875/0d511959be74/1472-6947-13-126-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8f1/3834875/f3fe34fbdb5e/1472-6947-13-126-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8f1/3834875/1fad3e003c99/1472-6947-13-126-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8f1/3834875/0095010d5a9e/1472-6947-13-126-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8f1/3834875/0d511959be74/1472-6947-13-126-4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8f1/3834875/f3fe34fbdb5e/1472-6947-13-126-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8f1/3834875/1fad3e003c99/1472-6947-13-126-2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8f1/3834875/0095010d5a9e/1472-6947-13-126-3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c8f1/3834875/0d511959be74/1472-6947-13-126-4.jpg

相似文献

1
Evaluation of prediction models for the staging of prostate cancer.前列腺癌分期预测模型的评估。
BMC Med Inform Decis Mak. 2013 Nov 15;13:126. doi: 10.1186/1472-6947-13-126.
2
Comparing 3-T multiparametric MRI and the Partin tables to predict organ-confined prostate cancer after radical prostatectomy.比较3-T多参数磁共振成像和Partin表预测前列腺癌根治术后器官局限性前列腺癌的情况。
Urol Oncol. 2014 Nov;32(8):1292-9. doi: 10.1016/j.urolonc.2014.04.017. Epub 2014 May 23.
3
Novel predictive tools for Irish radical prostatectomy pathological outcomes: development and validation.爱尔兰根治性前列腺切除术病理结局的新型预测工具:研发与验证。
Ir J Med Sci. 2010 Jun;179(2):187-95. doi: 10.1007/s11845-009-0393-6. Epub 2009 Jul 14.
4
Using support vector machine analysis to assess PartinMR: A new prediction model for organ-confined prostate cancer.使用支持向量机分析评估 PartinMR:一种新的预测模型,用于预测器官局限型前列腺癌。
J Magn Reson Imaging. 2018 Aug;48(2):499-506. doi: 10.1002/jmri.25961. Epub 2018 Feb 13.
5
External validation of the 2007 and 2001 Partin tables in Irish prostate cancer patients.2007年和2001年Partin表在爱尔兰前列腺癌患者中的外部验证。
Urol Int. 2010;84(2):174-9. doi: 10.1159/000277594. Epub 2010 Mar 4.
6
Machine learning for improved pathological staging of prostate cancer: a performance comparison on a range of classifiers.机器学习在前列腺癌病理分期中的应用:一系列分类器的性能比较。
Artif Intell Med. 2012 May;55(1):25-35. doi: 10.1016/j.artmed.2011.11.003. Epub 2011 Dec 27.
7
Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer.使用2005年国际泌尿病理学会关于Gleason分级的共识,对日本临床局限性前列腺癌患者进行Partin表验证及术前列线图的开发:来自局限性前列腺癌临床病理研究组的数据
J Urol. 2008 Sep;180(3):904-9; discussion 909-10. doi: 10.1016/j.juro.2008.05.047. Epub 2008 Jul 17.
8
Can Radiologic Staging With Multiparametric MRI Enhance the Accuracy of the Partin Tables in Predicting Organ-Confined Prostate Cancer?多参数磁共振成像的放射学分期能否提高Partin表预测局限性前列腺癌的准确性?
AJR Am J Roentgenol. 2016 Jul;207(1):87-95. doi: 10.2214/AJR.15.15878. Epub 2016 Apr 11.
9
Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer.预测包膜外侵犯的存在及范围:一种前列腺癌分期的列线图
J Urol. 2004 May;171(5):1844-9; discussion 1849. doi: 10.1097/01.ju.0000121693.05077.3d.
10
Implementing the use of nomograms by choosing threshold points in predictive models: 2012 updated Partin Tables vs a European predictive nomogram for organ-confined disease in prostate cancer.应用预测模型中的临界点来实施列线图的使用:2012 年更新版的 Partin 表格与前列腺癌器官局限疾病的欧洲预测列线图比较。
BJU Int. 2014 Jun;113(6):878-86. doi: 10.1111/bju.12532. Epub 2014 Feb 14.

引用本文的文献

1
Extracapsular extension risk assessment using an artificial intelligence prostate cancer mapping algorithm.使用人工智能前列腺癌映射算法进行包膜外扩展风险评估。
BJUI Compass. 2024 Aug 26;5(10):986-997. doi: 10.1002/bco2.421. eCollection 2024 Oct.
2
Diagnostic performance of prediction models for extraprostatic extension in prostate cancer: a systematic review and meta-analysis.前列腺癌前列腺外侵犯预测模型的诊断性能:一项系统评价和荟萃分析
Insights Imaging. 2023 Aug 22;14(1):140. doi: 10.1186/s13244-023-01486-7.
3
A Novel Risk Calculator Incorporating Clinical Parameters, Multiparametric Magnetic Resonance Imaging, and Prostate-Specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Risk Stratification Before Transperineal Prostate Biopsy.

本文引用的文献

1
Landmarks in prostate cancer diagnosis: the biomarkers.前列腺癌诊断的标志物:里程碑。
BJU Int. 2012 Oct;110 Suppl 1:8-13. doi: 10.1111/j.1464-410X.2012.011429.x.
2
Emerging biomarkers of prostate cancer (Review).前列腺癌的新兴生物标志物(综述)。
Oncol Rep. 2012 Aug;28(2):409-17. doi: 10.3892/or.2012.1832. Epub 2012 May 25.
3
Beyond PSA: the next generation of prostate cancer biomarkers.超越 PSA:前列腺癌下一代生物标志物。
一种新型风险计算器,纳入临床参数、多参数磁共振成像和前列腺特异性膜抗原正电子发射断层扫描,用于经会阴前列腺活检前的前列腺癌风险分层。
Eur Urol Open Sci. 2023 Jun 2;53:90-97. doi: 10.1016/j.euros.2023.05.002. eCollection 2023 Jul.
4
Value of machine learning-based transrectal multimodal ultrasound combined with PSA-related indicators in the diagnosis of clinically significant prostate cancer.基于机器学习的经直肠多模态超声联合 PSA 相关指标在诊断临床显著前列腺癌中的价值。
Front Endocrinol (Lausanne). 2023 Mar 8;14:1137322. doi: 10.3389/fendo.2023.1137322. eCollection 2023.
5
Integrating Serum Biomarkers into Prediction Models for Biochemical Recurrence Following Radical Prostatectomy.将血清生物标志物纳入根治性前列腺切除术后生化复发的预测模型
Cancers (Basel). 2021 Aug 19;13(16):4162. doi: 10.3390/cancers13164162.
6
Biosensors Designed for Clinical Applications.用于临床应用的生物传感器。
Biomedicines. 2021 Jun 22;9(7):702. doi: 10.3390/biomedicines9070702.
7
Application of Artificial Intelligence/Machine Vision & Learning for the Development of a Live Single-cell Phenotypic Biomarker Test to Predict Prostate Cancer Tumor Aggressiveness.人工智能/机器视觉与学习在开发用于预测前列腺癌肿瘤侵袭性的实时单细胞表型生物标志物检测中的应用。
Rev Urol. 2020;22(4):159-167.
8
A Decision Aide for the Risk Stratification of GU Cancer Patients at Risk of SARS-CoV-2 Infection, COVID-19 Related Hospitalization, Intubation, and Mortality.一种用于对有感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)、新型冠状病毒肺炎(COVID-19)相关住院、插管和死亡风险的泌尿生殖系统癌症患者进行风险分层的决策辅助工具。
J Clin Med. 2020 Aug 30;9(9):2799. doi: 10.3390/jcm9092799.
9
A risk calculator to inform the need for a prostate biopsy: a rapid access clinic cohort.用于告知前列腺活检需求的风险计算器:快速通道诊所队列。
BMC Med Inform Decis Mak. 2020 Jul 3;20(1):148. doi: 10.1186/s12911-020-01174-2.
10
The Diagnostic Performance of the Length of Tumor Capsular Contact on MRI for Detecting Prostate Cancer Extraprostatic Extension: A Systematic Review and Meta-Analysis.MRI 上肿瘤包膜接触长度诊断前列腺癌前列腺外侵犯的效能:系统评价和荟萃分析。
Korean J Radiol. 2020 Jun;21(6):684-694. doi: 10.3348/kjr.2019.0842.
Sci Transl Med. 2012 Mar 28;4(127):127rv3. doi: 10.1126/scitranslmed.3003180.
4
Cancer statistics, 2012.癌症统计数据,2012 年。
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.
5
Management of low (favourable)-risk prostate cancer.低(有利)风险前列腺癌的管理。
BJU Int. 2011 Dec;108(11):1684-95. doi: 10.1111/j.1464-410X.2010.10489.x.
6
Prediction models in cancer care.癌症护理中的预测模型。
CA Cancer J Clin. 2011 Sep-Oct;61(5):315-26. doi: 10.3322/caac.20118. Epub 2011 Jun 23.
7
Assessing the incremental value of diagnostic and prognostic markers: a review and illustration.评估诊断和预后标志物的附加价值:综述与实例。
Eur J Clin Invest. 2012 Feb;42(2):216-28. doi: 10.1111/j.1365-2362.2011.02562.x. Epub 2011 Jul 5.
8
Comparison of accuracy among three generations of Partin tables in a Chinese cohort.中国队列中三代帕廷表格准确性的比较。
Can J Urol. 2011 Apr;18(2):5619-24.
9
Active surveillance program for prostate cancer: an update of the Johns Hopkins experience.主动监测前列腺癌计划:约翰霍普金斯经验的更新。
J Clin Oncol. 2011 Jun 1;29(16):2185-90. doi: 10.1200/JCO.2010.32.8112. Epub 2011 Apr 4.
10
Biomarker research in prostate cancer--towards utility, not futility.前列腺癌的生物标志物研究——走向实用,而非徒劳。
Nat Rev Urol. 2011 Mar;8(3):131-8. doi: 10.1038/nrurol.2011.11.